Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Miyanaga, Akihiko ^a   Shimizu, Kumi ^a   Noro, Rintaro ^a   Seike, Masahiro ^a   Kitamura, Kazuhiro ^a   Kosaihira, Seiji ^a   Minegishi, Yuji ^a   Shukuya, Takehito ^g   Yoshimura, Akinobu ^a,h   Kawamoto, Masashi ^b,c   Tsuchiya, Shinichi ^b   Hagiwara, Koichi ^d   Soda, Manabu ^e   Takeuchi, Kengo ^f   Yamamoto, Nobuyuki ^g   Mano, Hiroyuki ^e   Ishikawa, Yuichi ^f   Gemma, Akihiko ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIPPON MEDICAL SCHOOL HOSPITAL   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f CANCER INSTITUTE   (Japan)

^g SHIZUOKA CANCER CENTER   (Japan)

^h TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

EGFR mutation; EML4 ALK; Lung cancer

Indexed keywords

ALK INHIBITOR; ANAPLASTIC LYMPHOMA KINASE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; THYROID TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADULT; ALK GENE; ARTICLE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOLERABILITY; EGFR GENE; EML4 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE MUTATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIODIC ACID SCHIFF STAIN; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINE METASTASIS; SPINE RADIOGRAPHY; THORACIC SPINE; TRANSTHORACIC BIOPSY; TREATMENT RESPONSE; TUMOR GENE; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROTO ONCOGENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENES, ERBB-1; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84878228369     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-262     Document Type: Article

References (20)

1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566. 10.1038/nature05945, 17625570.
2. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Can Res 2008, 14(20):6618-6624.
3. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Can Res 2008, 14(13):4275-4283.
4. Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 2008, 99(12):2349-2355. 10.1111/j.1349-7006.2008.00972.x, 19032370.
5. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009, 115(8):1723-1733. 10.1002/cncr.24181, 19170230.
6. Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008, 10(3):298-302. 2259458, 18320074.
7. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008, 3(1):13-17. 10.1097/JTO.0b013e31815e8b60, 18166835.
8. Shinmura K, Kageyama S, Tao H, Bunai T, Suzuki M, Kamo T, Takamochi K, Suzuki K, Tanahashi M, Niwa H. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 2008, 61(2):163-169. 10.1016/j.lungcan.2007.12.013, 18242762.
9. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703. 10.1056/NEJMoa1006448, 3014291, 20979469.
10. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, Fukuyama S, Yokote A, Kobayashi K, Kanazawa M. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005, 65(16):7276-7282. 10.1158/0008-5472.CAN-05-0331, 16105816.
11. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388. 10.1056/NEJMoa0909530, 20573926.
12. Popat S, Vieira de Araujo A, Min T, Swansbury J, Dainton M, Wotherspoon A, Lim E, Nicholson AG, O'Brien ME. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol 2011, 6(11):1962-1963. 10.1097/JTO.0b013e31822eec5e, 22005476.
13. Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, Bozzetti C, Sammarelli G, Thai E, Ardizzoni A. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 2011, 71(2):241-243. 10.1016/j.lungcan.2010.11.014, 21168933.
14. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011, 71(18):6051-6060. 10.1158/0008-5472.CAN-11-1340, 3278914, 21791641.
15. Tanaka H, Hayashi A, Morimoto T, Taima K, Tanaka Y, Shimada M, Kurose A, Takanashi S, Okumura K. A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene. BMC Cancer 2012, 12(1):558. 10.1186/1471-2407-12-558, 3515412, 23181703.
16. Kuo YW, Wu SG, Ho CC, Shih JY. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol 2010, 5(12):2039-2040. 10.1097/JTO.0b013e3181f43274, 21102267.
17. Lee JK, Kim TM, Koh Y, Lee SH, Kim DW, Jeon YK, Chung DH, Yang SC, Kim YT, Kim YW. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lung Cancer 2012, 77(2):460-463. 10.1016/j.lungcan.2012.04.012, 22622260.
18. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29(21):2866-2874. 10.1200/JCO.2010.33.4235, 21670455.
19. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128. 10.1016/S1470-2045(09)70364-X, 20022809.
20. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27(26):4247-4253. 10.1200/JCO.2009.22.6993, 2744268, 19667264.